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Recent research suggests genetic variation in the Klotho locus may modify the association 30 
between APOE e4 and cognitive impairment. We tested for associations and interactions 31 
between these genotypes vs. risk of dementia, cognitive abilities, and brain structure in older 32 
UK Biobank participants. Klotho status was indexed with rs9536314 heterozygosity (vs. not), 33 
in unrelated people with vs. without APOE e4 genotype, corrected for various confounders. 34 
APOE e4 associated with increased risk of dementia, worse cognitive abilities and brain 35 
structure. Klotho was associated with better reasoning. There were no interactions; potentially 36 
suggesting an age- and pathology-dependent Klotho effect.  37 
 38 
Key points 39 
• Question: Klotho genotype has been previously shown to ‘offset’ a substantial amount of 40 
the APOE e4/cognitive impairment association. Is this modification effect apparent in 41 
large-scale independent data, in terms of non-demented cognitive abilities, brain 42 
structure and dementia prevalence?  43 
• Findings: In aged 60 years and above participants from UK Biobank, we found 44 
significant associations of APOE and Klotho genotypes on cognitive, structural brain and 45 
dementia outcomes, but no significant interactions. 46 
• Meaning: This could reflect somewhat healthy participants, prior type 1 error or 47 
cognitive/dementia ascertainment imprecision, and/or that Klotho genotypic effects are 48 




Preserving cognitive abilities such as memory is a common concern into older age, and in the 51 
absence of reliable treatments, the public health priority is prevention and delay of cognitive 52 
impairment1, including understanding effect modifiers. APOE e4 is a known risk factor for AD 53 
and cognitive decline1. Genetic variation in the KL locus has been associated with ageing-54 
related phenotypes including insulin resistance and brain function2. A recent study of AD 55 
cohorts, longitudinal conversion and amyloid-beta samples showed a statistically significant 56 
‘modification’ effect where the deleterious effects conferred by APOE e4 were offset by 57 
heterozygosity based on two KL polymorphisms in strong linkage disequilibrium: F352V 58 
(rs9536314) and C370S (rs9527025), possibly due to correlations with increased serum 59 
Klotho3. UK Biobank is a relatively large general population cohort4 where we have previously 60 
shown deleterious effects of APOE e4 on cognitive5, structural brain imaging6 and 61 
AD/dementia phenotypes7. This brief report tested the hypothesis that based on recent 62 
research, genetic KL variation would interact with APOE e4 genotype in relevant cognitive, 63 
brain and dementia phenotypes.  64 
 65 
Methodology 66 
Study design and participants 67 
UK Biobank is a prospective cohort study including 502,628 participants who attended one of 68 
22 baseline assessment centres from 2006 to 2010, aged 40-70 years8. In 2014, MRI scanning 69 
of a sub-group of 100,000 participants began, and this is ongoing. This project was completed 70 
using UK Biobank application #17689 except for the hospital admission and episode (HES) 71 
analyses which were conducted using project #7155. 72 
 73 
Ethical approval and data availability This analysis was conducted under generic approval 74 
from the NHS National Research Ethics Service (approval letter dated 17th June 2011, ref 75 
11/NW/0382). Written informed consent was obtained from all participants in the study.   76 
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Dementia outcomes 77 
Dementia/AD outcomes were generated in two ways: firstly, derived by UK Biobank using self-78 
report, hospital admission and death record data, with data utilising International Classification 79 
of Diseases version 10 (ICD-10 codes). Individuals were designated as cases (“all-cause 80 
dementia” or “Alzheimer disease”) if they had indicated either in self-report or hospital/death 81 
records – derived by UK Biobank7,9. Those coded as missing were designated as controls (i.e. 82 
did not self-report dementia, and diagnoses not present in hospital/death records). The UK 83 
Biobank-derived ascertained cases were the latest available as of October 2020. Secondly 84 
we supplemented this with record-based hospital admission/episode (HES) data using open-85 
access methods described previously10 where dementia was defined as ICD-10 codes F00 86 
(dementia in Alzheimer disease), F01 (vascular dementia), F02 (dementia in other diseases), 87 
or F03 (unspecified dementia); hospital admission records were available until February 2018 88 
for the full cohort, whereas linkage to primary care records was available for 45% of the UK 89 
Biobank cohort (approximately 230 000 participants) until May 2017, for Scotland, September 90 
2017, for Wales, and August 2017 for England.  91 
 92 
Imaging data 93 
The release of brain MRI data as of July 2020 was used (i.e. approximately 40k). All imaging 94 
data used here was processed and quality checked by UK Biobank11. We selected imaging 95 
phenotypes a priori shown to be associated with worse cognitive ability and decline total white 96 
and grey volumes adjusted for skull size (WM/GM respectively);  log WM hyperintensity 97 
volume (WMH); overall hippocampal volume; general factors of fractional anisotropy (FA) and 98 
mean diffusivity (MD), and frontal lobe GM (gFrontal)12 based on principal components 99 
analysis (PCA). Total WM hyperintensity volumes were calculated based on T1 and T2 fluid-100 
attenuated inversion recovery (FLAIR), derived by UK Biobank.  101 
 102 
Cognitive data 103 
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Five tests were completed at baseline (2006-2010), of which we examine three here which 104 
have shown sufficient intra-participant reliabilities: Pairs-matching 6-pair (memory), verbal-105 
numeric reasoning and log reaction time (processing speed)13. We also examined four 106 
cognitive tests administered from 2014 onwards. These were: Trail making test a+b 107 
(processing speed/executive function) and Digit symbol substitution (executive function) 108 
assessed via online follow-up, plus Matrix pattern completion (nonverbal reasoning) and 109 
Tower rearranging (executive function) at MRI12. 110 
 111 
Genetic data  112 
UK Biobank genotyping was conducted by Affymetrix using a bespoke BiLEVE Axiom array 113 
for ∼50,000 participants and the remaining ∼450,000 on the Affymetrix UK Biobank Axiom 114 
array. All genetic data were quality controlled by UK Biobank as described by the protocol 115 
paper4.). APOE e4 ‘risk’ genotype presence (vs. non-e4) was genotyped based on rs7412 and 116 
rs429358. KL was indexed using rs9536314 where G/T is considered protective (vs. G/G; T/T) 117 
and synonymous with KL-VS diplotype heterozygosity14.  118 
 119 
Covariates 120 
Participants self-reported their smoking history: current, past or never, medication use for 121 
dyslipidaemia, hormone replacement therapy, blood pressure, oral contraceptive or insulin. 122 
We excluded participants for whom these data were missing (<5%). Townsend deprivation 123 
indices were derived from postcode of residence.  124 
 125 
Statistical analysis  126 
PLINK v1.90 was used for genetic quality controlling and Stata V.14 was used for statistical 127 
analyses. We removed participants who reported neurological conditions as described 128 
previously13. We statistically controlled for: age, sex, Townsend, ever-smoking, genotypic 129 
array, baseline/MRI assessment centre, 8 principal components, array, and medication 130 
(concurrent to the phenotype under study; dementia outcomes used baseline values). We 131 
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focussed on participants aged ≥60 years at baseline or imaging (respectively for those 132 
analyses)3. We excluded participants with non-white British ancestry, self-report vs. genetic 133 
sex mismatch, putative sex chromosomal aneuploidy and excess heterozygosity. In terms of 134 
quality controlling we accounted for relatedness between participants by removing one 135 
random participant in cases where two individuals were 2nd cousins or closer, and this was 136 
based on central UK Biobank-derived relatedness coefficients 137 
(https://biobank.ndph.ox.ac.uk/ukb/label.cgi?id=263). We included polymorphisms in Hardy 138 
Weinberg equilibrium (P > 1*10-6), polymorphisms with missingness rate less than 0.1 and 139 
minor allele frequency> 0.01 and imputation score > 0.8. We have previously reported power 140 
calculations indicative of >95% confidence to find ‘true’ effect sizes at Cohen’s D = 0.1 (i.e. 141 
small) with regard to APOE genotype and outcomes in UK Biobank6. Multiple power 142 
calculations using G*Power 2, for a ‘true’ effect at Cohen’s D = 0.1 (where 0.2 is considered 143 
a small effect size) at p=0.05, estimated the least power to find a ‘true’ effect was in the imaging 144 
sample, with 96% estimated power post-hoc based on current group sample sizes.  145 
 146 
Results 147 
Descriptives   148 
After exclusions there were baseline N=169,374 (mean age 64.1, SD=2.89) participants; 149 
imaging n=26,903 (68.14 years; SD 5.02). Allele frequencies for baseline/imaging analyses 150 
are shown in Supplementary Table 1. There were n=1,570 UKB-ascertained dementia cases 151 
(0.9%) of which n=634 were AD (0.4%). There were n=3,346 (1.9%) dementia cases based 152 
on HES of which n=1,577 (0.9%) were AD.  153 
 154 
Outcomes 155 
Supplementary Table 2 shows associations between APOE e4 genotype and multiple worse 156 
outcomes: UK Biobank-ascertained dementia (odds ratio[OR]=3.27 for e4 vs. not) and AD 157 
(OR=5.06), HES-based dementia (OR = 3.27) and AD (OR=5.06), cognitive scores on Matrix 158 
Completion (-0.04 SDs for e4 vs. not), frontal lobe GM (-0.05), hippocampal volume (-0.06), 159 
7 
 
log TMT total time (0.037) and Digit symbol (-0.075; significant P-value range <0.001 to 0.038). 160 
KL heterozygosity (vs. not) was associated with better reasoning only (0.021SDs; P=0.042). 161 
There were no statistically significant APOE/KL interactions.  162 
 163 
As sensitivity analyses all models were re-run: unadjusted then covariates added 164 
incrementally; excluding people with concurrent neurological conditions13; testing a dose effect 165 
of 0/1/2 G allele copies (i.e. including an extra n=4,489 with GG) rather than the primary T/T 166 
vs. G/T test throughout, and using the full sample (aged <60). These made no difference to 167 
the results.  168 
 169 
Discussion 170 
A recent study by Belloy et al.3  reported a protective modifying effect of KL heterozygosity on 171 
APOE e4 genotype’s conferred risk on cognitive impairment and dementia, in a collation of 172 
longitudinal, AD and amyloid-beta cohorts totalling N=24,743. Using unrelated UK Biobank 173 
data we tested whether a similar effect could be seen in multiple outcomes: AD/all-cause 174 
dementia vs. not, and non-demented cognitive and structural brain MRI phenotypes known to 175 
underlie cognitive decline. Participants were ≥60 years as per Belloy et al. We identified 176 
individual APOE and KL genotype/outcome associations but no interactions, against our 177 
hypothesis. There could be an underestimation of true effect due to cognitive test imprecision13 178 
or generally preserved participant health12. No interaction here vs. Belloy et al. could reflect 179 
the use of different phenotypes: the original study investigated AD case vs. control status, 180 
conversion to impairment and amyloid-beta while this study investigated AD status and non-181 
demented cognitive/brain structure values. UK Biobank derived dementia status largely from 182 
ICD codes whereas Belloy et al. used clinical and/or pathological ascertainment. This could 183 
suggest that the age-dependent changes in KL expression, and interaction with APOE status, 184 
manifest only beyond at least moderate AD-related neuropathology (e.g. amyloid or tau)15. 185 
The null AD case/control interaction could reflect that UK Biobank is relatively healthy and 186 
well-educated. It is possible the UK Biobank participants were not sufficiently old; analysis of 187 
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longitudinal cognitive and brain imaging data (in independent data) is indicative of more 188 
pronounced KL heterozygosity effects particularly into later life16. By contrast our findings are 189 
more in-line with de Vries et al.16 who reported protective rather than deleterious effects of KL 190 
heterozygosity on longitudinal cognitive decline.  191 
 192 
Limitations 193 
This study did not explore an exhaustive list of structural imaging phenotypes. There is some 194 
degree of healthy volunteer bias in UK Biobank participants, and probably more so in 195 
participants who returned for imaging. Some imaging participants would have been unable to 196 
complete scanning due to contraindications related to poorer health, e.g. pacemakers/stents12. 197 
Dementia ascertainment was based on a mixture of self-report, HES and death data; 198 
participants did not have regular cognitive assessment e.g. with Mini-Mental State Exam, and 199 
hence there may be some degree of underestimation of dementia in the current data.  200 
 201 
Summary 202 
A recent relatively large-scale study including cohort, case/control longitudinal and amyloid-203 
beta data showed a significant interaction whereby KL genotype modified the well-known 204 
APOE e4 and dementia association. Using independent cognitive, structural brain and 205 
dementia data, we did not support these prior findings; this could reflect some degree of bias 206 
or imprecision in UK Biobank participants or phenotypes, or that the interaction while ‘true’ is 207 
contingent on AD-related neuropathology: future studies should investigate this further in 208 
deeply-phenotyped cohorts.  209 
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